期刊
LUNG CANCER
卷 78, 期 3, 页码 239-244出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2012.08.017
关键词
Bevacizumab; Erlotinib; Non-squamous NSCLC; Metastatic; Translational research; First-line regimen
资金
- Swiss State Secretariat for Education and Research (SER)
- Roche Pharma (Schweiz) AG
Purpose: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). Methods: 103 patients with advanced non-squamous NSCLC were treated with B (15 mg/kg day 1 of each 21-day cycle) and E (150 mg daily) until PD or unacceptable toxicity. Upon PD patients received 6 cycles of CT (cisplatin/carboplatin and gemcitabine). The primary endpoint was disease stabilization rate (DSR) after 12 weeks of BE treatment. Results: 101 patients were evaluable. Under BE. DSR at week 12 was 54.5%. 73 patients had at least stable disease (SD). including 1 complete remission and 17 partial responses (PR). No unexpected toxicities were observed. Median time to progression (UP) under BE was 4.1 months. 62 patients started CT; 35 received at least 4 cycles (6 PR, 32 SD). At a median follow-up of 36 months, median overall survival (OS) was 14.1 months. Conclusions: First-line BE treatment followed by a fixed CT regimen at PD is feasible with acceptable toxicity and activity. In a non-squamous NSCLC population unselected for EGFR status, we found OS rates similar to standard CT. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据